Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026-11 · 24 (11) · 1577-1585
DOI: 10.1111/ddg.70051 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 14.04.2026. Verfasst von Alfonso Gotor-Rivera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital "12 de Octubre", Madrid, Spain. Hauptthemen laut MEDLINE: Psoriasis, Neoplasms, Biological Therapy, Biological Products. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background and objectives Evidence‐based recommendations for the treatment of patients with psoriatic disease (PsO) and a prior history of malignancy are limited. This study aimed to compare the incidence of newly diagnosed neoplasms among patients with PsO and a previous malignancy receiving treatment with conventional systemic therapies, apremilast, or biologic agents. Patients and methods Retrospective observational study using TriNetX. PsO patients (ICD10:L40) with a previous diagnosis of cancer (ICD10:C00‐D49) less than 5 years prior to systemic therapy initiation were selected. Outcomes evaluated included new documentation of neoplasms and all‐cause mortality.
Results
Patients under biologic therapy had a significantly lower new neoplasm documentation rate and all‐cause mortality compared to classical agents (HR 0.857 and HR 0.705, respectively) and apremilast (HR 0.782 and HR 0.803, respectively) at 3 years follow‐up. Only TNFi exhibited a significantly lower new neoplasm rate (HR 0.867, p < 0.0001) compared to classical agents; however, all biologic agents significantly decreased mortality. IL‐23i was the only biologic therapy to significantly lower cancer recurrence risk (RR 0.878) compared to TNFi, with no differences in all‐cause mortality.
Conclusions
Biologic therapy for PsO may represent a safe treatment option in patients with a history of malignancy, compared with conventional systemic therapies or apremilast. Among biologic agents, IL‐23 inhibitors appear to be associated with the most favorable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital "12 de Octubre", Madrid, Spain.
- Digital Health Group, Research Institute University Hospital "12 de Octubre", Madrid, Spain.
- Department of Medicine, Complutense University, Madrid, Spain.
ORCID-Profile: Alfonso Gotor-Rivera
Zitieren
APA
Gotor-Rivera, A., Hernández-Sánchez, J., Chamorro-Jiménez, E., García-Rivera, E., Ortiz-Romero, P., García-Donoso, C., & Rivera-Díaz, R. (2026). Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 24(11), 1577-1585. https://doi.org/10.1111/ddg.70051
Vancouver
Gotor-Rivera A, Hernández-Sánchez J, Chamorro-Jiménez E, García-Rivera E, Ortiz-Romero P, García-Donoso C, et al. Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026;24(11):1577-1585. doi:10.1111/ddg.70051
BibTeX
@article{GotorRivera2026,
author = {Gotor-Rivera, Alfonso and Hernández-Sánchez, Julia and Chamorro-Jiménez, Eva and García-Rivera, Emilia and Ortiz-Romero, Pablo and García-Donoso, Carmen and Rivera-Díaz, Raquel},
title = {Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
volume = {24},
number = {11},
pages = {1577--1585},
doi = {10.1111/ddg.70051}
}
EUVIMED